MARKET

AKCA

AKCA

Akcea
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.10
-1.05
-5.48%
After Hours: 18.10 0 0.00% 16:00 01/24 EST
OPEN
19.13
PREV CLOSE
19.15
HIGH
19.54
LOW
17.81
VOLUME
396.82K
TURNOVER
--
52 WEEK HIGH
35.82
52 WEEK LOW
13.90
MARKET CAP
1.70B
P/E (TTM)
-13.1569
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AKCA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AKCA News

  • Company News for Jan 23, 2020
  • Zacks.3d ago
  • Akcea Therapeutics and Ionis Pharmaceuticals' Triglyceride-Lowering Drug AKCEA-APOCIII-LRx Works in Mid-Stage Clinical Trial
  • MotleyFool.com.4d ago
  • Will These Biotechs Rival A Top-Notch Stock In High Triglycerides?
  • Investor's Business Daily.4d ago
  • Akcea antisense candidate successful in mid-stage hypertriglyceridemia study
  • seekingalpha.4d ago

More

Industry

Pharmaceuticals
-1.84%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About AKCA

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).
More

Webull offers Akcea Therapeutics Inc (AKCA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.